Positioning a Global Pharmaceutical Company’s HIV Portfolio to Capture Emerging Opportunities

Shift Health was engaged to support a top-5 global pharmaceutical company in defining its role and priorities in the evolving HIV disease management landscape.

Shift Health carried out a comprehensive evaluation and prioritization of emerging opportunities—specific preventive and therapeutic concepts and technologies—in the external HIV research and development environment, identified strategic international partners and partnership models, and supported the development of an evidence-based Strategic Investment Roadmap for the company’s HIV portfolio.

Shift Health’s scientifically rigorous Strategic Investment Roadmap for the HIV program has enabled the company to create new value and advance both corporate priorities and global health objectives.